BMC Public Health (Jan 2011)

Prevention of type 2 diabetes in a primary healthcare setting: Three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance

  • Usui Takeshi,
  • Sato Yuzo,
  • Kawazu Shoji,
  • Tominaga Makoto,
  • Tsuzaki Kokoro,
  • Kotani Kazuhiko,
  • Tsujii Satoru,
  • Tsushita Kazuyo,
  • Sato Juichi,
  • Sakane Naoki,
  • Kamae Isao,
  • Yoshida Toshihide,
  • Kiyohara Yutaka,
  • Sato Shigeaki,
  • Kuzuya Hideshi

DOI
https://doi.org/10.1186/1471-2458-11-40
Journal volume & issue
Vol. 11, no. 1
p. 40

Abstract

Read online

Abstract Background A randomized control trial was performed to test whether a lifestyle intervention program, carried out in a primary healthcare setting using existing resources, can reduce the incidence of type 2 diabetes in Japanese with impaired glucose tolerance (IGT). The results of 3 years' intervention are summarized. Methods Through health checkups in communities and workplaces, 304 middle-aged IGT subjects with a mean body mass index (BMI) of 24.5 kg/m2 were recruited and randomized to the intervention group or control group. The lifestyle intervention was carried out for 3 years by public health nurses using the curriculum and educational materials provided by the study group. Results After 1 year, the intervention had significantly improved body weight (-1.5 ± 0.7 vs. -0.7 ± 2.5 kg in the control; p = 0.023) and daily non-exercise leisure time energy expenditure (25 ± 113 vs. -3 ± 98 kcal; p = 0.045). Insulin sensitivity assessed by the Matsuda index was improved by the intervention during the 3 years. The 3-year cumulative incidence tended to be lower in the intervention group (14.8% vs.8.2%, log-rank test: p = 0.097). In a sub-analysis for the subjects with a BMI > 22.5 kg/m2, a significant reduction in the cumulative incidence was found (p = 0.027). Conclusions The present lifestyle intervention program using existing healthcare resources is beneficial in preventing diabetes in Japanese with IGT. This has important implications for primary healthcare-based diabetes prevention. Trial registration number UMIN000003136